FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
News|Articles|March 2, 2005
- Pharmaceutical Technology-03-02-2005
- Volume 29
- Issue 3
Managing Aseptic Interventions
Author(s)James P. Agalloco
This article outlines a comprehensive approach for organizing a firm's aseptic operations, including planning for routine and nonroutine interventions, establishing effective process simulations, and determining which vials to incubate.
Advertisement
Articles in this issue
over 21 years ago
March 2005over 21 years ago
Packaging Becomes Part of the Prescriptionover 21 years ago
Appraisal of the Laser Diffraction Particle-Sizing Techniqueover 21 years ago
Optimism Taking Over in Pharmaceutical Chemicalsover 21 years ago
In the Spotlight - March 2005over 21 years ago
A “Disclosure Defense” in Liability Lawover 21 years ago
Validating Automated Systemsover 21 years ago
Combination Products Raise Manufacturing ChallengesAdvertisement
Related to this article
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.
Roche-Hansoh, Merck KGaA-Silence, and Lilly-METiS deals show how ADCs, siRNA, and lipid nanoparticles reshape demands on CMC and manufacturing teams.
Germany is home to several prominent pharma companies and more than 1000 innovative biotechs.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
3
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
4
Nitrosamine Problems and Industry Solutions: PharmTech Explained
5